Abstract:Tauopathies are a class of neurodegenerative diseases, including Alzheimer's disease (AD), Frontotemporal Dementia (FTD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), and many others where microtubule-associated protein tau (MAPT or tau) is hyperphosphorylated and aggregated to form insoluble paired helical filaments (PHFs) and ultimately neurofibrillary tangles (NFTs). Autophagic-endolysosomal networks (AELN) play important roles in tau clearance. Excessive soluble neurotoxic forms of tau and tau hyperphosphorylated at specific sites are cleared through the ubiquitin-proteasome system (UPS), Chaperon-mediated Autophagy (CMA), and endosomal microautophagy (e-MI). On the other hand, intra-neuronal insoluble tau aggregates are often degraded within lysosomes by macroautophagy. AELN defects have been observed in AD, FTD, CBD, and PSP, and lysosomal dysfunction was shown to promote the cleavage and neurotoxicity of tau. Moreover, several AD risk genes (e.g., PICALM, GRN, and BIN1) have been associated with dysregulation of AELN in the late-onset sporadic AD. Conversely, tau dissociation from microtubules interferes with retrograde transport of autophagosomes to lysosomes, and that tau fragments can also lead to lysosomal dysfunction. Recent studies suggest that tau is not merely an intra-neuronal protein, but it can be released to brain parenchyma via extracellular vesicles, like exosomes and ectosomes, and thus spread between neurons. Extracellular tau can also be taken up by microglial cells and astrocytes, either being degraded through AELN or propagated via exosomes. This article reviews the complex roles of AELN in the degradation and transmission of tau, potential diagnostic/therapeutic targets and strategies based on AELN-mediated tau clearance and propagation, and the current state of drug development targeting AELN and tau against tauopathies.

Tau internalization: A complex step in tau propagation

Tau Internalization is Regulated by 6-O Sulfation on Heparan Sulfate Proteoglycans (HSPGs)

Dysfunction of Microtubule-Associated Proteins of MAP2/tau Family in Prion Disease

Dysfunction of microtubule-associated proteins of MAP2/tau family in Prion disease.

Role of the endolysosomal pathway and exosome release in tau propagation

Fate and propagation of endogenously formed Tau aggregates in neuronal cells

Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds

Possible Mechanisms of Tau Spread and Toxicity in Alzheimer’s Disease

Mechanistic Insights and Future Challenges

Tau seeds translocate across the cell membrane to initiate aggregation

Compromised function of the ESCRT pathway promotes endolysosomal escape of tau seeds and propagation of tau aggregation

Microglia undergoes chemokine receptor, CX3CR1-mediated internalization of extracellular Tau

Interaction of full-length Tau with negatively charged lipid membranes leads to polymorphic aggregates

Tau in physiology and pathology

Role of the Lipid Membrane and Membrane Proteins in Tau Pathology

Tau in neurodegenerative diseases: molecular mechanisms, biomarkers, and therapeutic strategies

Purinergic Receptor P2Y12-Mediated Tau Internalization in Microglia

The Structure Biology of Tau and Clue for Aggregation Inhibitor Design

Tau in neurodegenerative disease

Degradation and Transmission of Tau by Autophagic-Endolysosomal Networks and Potential Therapeutic Targets for Tauopathy

Filamentous recombinant human Tau activates primary astrocytes via an integrin receptor complex